BioHarvest Sciences (NASDAQ:BHST) Shares Climb 1.4% – What’s Next?

BioHarvest Sciences Inc. (NASDAQ:BHST) traded up 1.4% during trading on Tuesday. The company traded as high as $1.52 and last traded at $1.47. 69,597 shares were traded during mid-day trading, an increase of 113% from the average session volume of 32,657 shares. The stock had previously closed at $1.45.

Wall Street Analysts Forecast Growth

BHST has been the subject of a number of research analyst reports. Roth Capital decreased their price objective on shares of BioHarvest Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of BioHarvest Sciences in a research note on Monday, September 14th. Finally, Maxim Group reduced their target price on shares of BioHarvest Sciences from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, August 12th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $6.50.

BioHarvest Sciences Trading Up 1.4%

The firm has a market cap of $28.84 million, a P/E ratio of -2.83 and a beta of 0.94. The business has a 50-day moving average price of $1.93 and a 200-day moving average price of $3.09.

BioHarvest Sciences (NASDAQ:BHST) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.04). BioHarvest Sciences had a negative net margin of 31.21% and a negative return on equity of 58.30%. The firm had revenue of $8.84 million during the quarter, compared to the consensus estimate of $9.45 million. On average, equities analysts anticipate that BioHarvest Sciences Inc. will post -0.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioHarvest Sciences

Several hedge funds have recently modified their holdings of BHST. Thompson Siegel & Walmsley LLC bought a new position in shares of BioHarvest Sciences during the fourth quarter valued at approximately $1,945,000. True North Advisors LLC raised its stake in BioHarvest Sciences by 381.0% in the first quarter. True North Advisors LLC now owns 168,013 shares of the company’s stock worth $729,000 after buying an additional 133,085 shares in the last quarter. Finally, Silverberg Bernstein Capital Management LLC purchased a new stake in BioHarvest Sciences during the first quarter worth $113,000.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company developing and commercializing products made with its proprietary Botanical Synthesis technology. The company’s platform is designed to produce specific plant-based compounds, including polyphenols, without growing the entire plant. BioHarvest says the process may help generate consistent, standardized botanical ingredients for use in health and wellness products and pharmaceutical development.

The company’s principal commercial product is VINIA, a powdered whole-fruit botanical ingredient derived from red grape cells and marketed for its polyphenol content.